Astrotech Corporation — Form 10-K Summary
Period: Fiscal year ended June 30, 2016. The request metadata says “2014 Q4,” but the supplied filing is a 2016 annual report, not a 2014 quarterly filing.
Business context
Astrotech develops and commercializes early-stage technologies through its Astro Scientific and Astral business units. Astro Scientific includes 1st Detect, which develops chemical detection instruments, and Astrogenetix, which is pursuing a Salmonella vaccine using microgravity research. Astral provides film digitization, restoration, and 4K/HDR conversion products and services. The former Astrotech Space Operations (ASO) business was sold to Lockheed Martin in August 2014.
Financial results and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $2.671 million | $0.513 million |
| Gross profit / margin | $0.339 million / 13% | $0.089 million / 17% |
| Operating expenses | $14.177 million | $16.200 million |
| Net loss from continuing operations | $13.434 million | $9.946 million |
| Net income (loss) attributable to Astrotech | $(13.095) million | $10.778 million |
| Continuing-operations operating cash flow | $(13.324) million | $(5.513) million |
| Cash and cash equivalents at year-end | $4.399 million | $2.330 million |
- Revenue increased $2.158 million, or 421%, primarily from research-based government subcontract work and $242,000 of space-grade handrail sales. Three customers represented all FY2016 revenue; the NGCD partner accounted for 61%, the DHS S&T partner 30%, and a Japanese aerospace company 9%.
- Gross margin fell four percentage points, with management citing higher labor costs on government subcontract agreements. SG&A declined $5.258 million, mainly because FY2015 included substantial equity-compensation and ASO-sale legal costs. R&D rose $3.235 million to $6.469 million as development investment increased.
- Total assets were $30.523 million, current liabilities $1.800 million, and total liabilities $1.896 million at June 30, 2016. The company reported no debt or credit facilities. Working capital was approximately $21.1 million; cash and investments totaled approximately $25.7 million.
- Continuing-operations investing activities provided $9.433 million, mainly from investment sales and maturities; continuing-operations financing activities used $0.140 million. Cash increased $2.069 million overall, including $6.1 million received from the ASO sale indemnity escrow.
Changes, outlook, risks, and unusual items
- FY2015’s $10.778 million attributable net income included $20.601 million of after-tax income from discontinued operations, including the ASO sale gain. FY2016 had no discontinued-operations income; the continuing-operations loss widened.
- Astrotech received the full $6.1 million ASO indemnity holdback in February 2016, with no claims asserted. The company said existing cash and cash equivalents were sufficient for expected expenses and liquidity needs for the coming year. It provided no quantified revenue or earnings guidance.
- 1st Detect advanced through stages of the Department of Defense NGCD development program and partnered on DHS S&T next-generation explosives trace detection work. These programs remain development opportunities, not assurance of future procurement or commercial sales.
- A material weakness in internal control over financial reporting involved revenue-recognition policies: certain contracts were initially treated as multiple-element arrangements instead of construction-/production-type contracts. The error understated revenue through March 31, 2016; it was corrected in the fourth quarter and deemed immaterial to previously issued statements. Management concluded disclosure controls were ineffective and described remediation steps.
- Key risks include continued operating losses and cash burn, dependence on a small number of customers and government programs, market acceptance and product-development milestones, government funding and procurement uncertainty, competition, and Astral’s ability to capture demand for 4K/HDR conversions. Management’s liquidity outlook is forward-looking and subject to these risks.
Important facts for investors to verify
- Whether government development contracts progress to production or procurement awards, and the timing and economics of any resulting sales.
- Customer concentration, contract backlog, revenue-recognition judgments, and whether the reported contract assets and estimates are collectible and realizable.
- Progress and effectiveness of remediation for the disclosed material weakness in revenue accounting and internal controls.
- Cash and investment balances, operating cash burn, and the assumptions behind management’s stated one-year liquidity sufficiency.
- Astral’s commercial traction and the costs required to develop its 4K/HDR products, and the funding and regulatory milestones for Astrogenetix’s vaccine program.